Angiogenesis Facilitated by Autologous Whole Bone Marrow Stem Cell Transplantation for Buerger's Disease

Division of Vascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Kangnamku, Seoul 135-710, Korea.
Stem Cells (Impact Factor: 6.52). 06/2006; 24(5):1194-200. DOI: 10.1634/stemcells.2005-0349
Source: PubMed

ABSTRACT We hypothesized that angiogenesis can be triggered by autologous whole bone marrow stem cell transplantation. Twenty-seven patients (34 lower limbs) with Buerger's disease, who were not candidates for surgical revascularization or radiologic intervention, were enrolled in this study. Six sites of the tibia bone were fenestrated using a 2.5-mm-diameter screw under fluoroscopic guidance. Clinical status and outcome were determined using the "Recommended Standards for Reports." To mobilize endothelial progenitor cells (EPCs) from bone marrow, recombinant human granulocyte colony-stimulating factor (r-HuG-CSF) was injected subcutaneously as a dose of 75 microg, preoperatively. During the follow-up period (19.1 +/- 3.5 months), one limb showed a markedly improved outcome (+3), and 26 limbs showed a moderately improved outcome (+2). Thirteen limbs among 17 limbs with nonhealing ulcers healed. Postoperative angiograms were obtained for 22 limbs. Two limbs showed marked (+3), five limbs moderate (+2), and nine limbs slight (+1) collateral development. However, six limbs showed no collateral development (0). Peripheral blood and bone marrow samples were analyzed for CD34 and CD133 molecules to enumerate potential EPCs, and EPC numbers were found to be increased in peripheral blood and in bone marrow after r-HuG-CSF injection. In conclusion, the transplantation of autologous whole BMCs by fenestration of the tibia bone represents a simple, safe, and effective means of inducing therapeutic angiogenesis in patients with Buerger's disease.

21 Reads
  • Source
    • "In the era of new endovascular therapy such as subintimal recanalization, laser-assisted techniques, and flexible or covered stents on the SFA, conventional vascular surgery appears to be on the decline [11,12,13]. Nevertheless, while it is appealing to use endovascular treatment for SFA in TASC C and D lesions and reserve surgery for cases of failed endovascular therapy, the long-term results of PTA are currently inferior to those of surgery [1,2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose Infrainguinalfemoropopliteal bypass (IFPB) is recommended to peripheral arterial disease (PAD) with a long occlusion of the superficial femoral artery (SFA). The aims of our study were to determine the patency of graft materials, and identify the risk factors of graft failure. Methods From January 1995 to April 2011, we had performed 380 IFPBs in 351 patients, including 302 femoro-above the knee (AK) bypasses and 78 femoro-below the knee (BK) bypasses. We compare age, sex, severity of ischemia between polytetra-uoroethylene (PTFE) graft and saphenous vein (SV) graft, and evaluate patency rate rates of the two groups. Results The primary patency rates at 5 years for SV (n = 76 limbs) and PTFE grafts (n = 226 limbs) in AK were 85.2% and 64.5% (log rank = 0.03), and the secondary patency rates at 5 years for SV and PTFE grafts in AK were 88.2% and 79.0% (log rank = 0.13). The primary patency rates at 5 years for SV (n = 50 limbs) and PTFE grafts (n = 28 limbs) in BK were 63.2% and 40.0% (log rank = 0.08), and the secondary patency rates at 5 years for SV and PTFE grafts in BK were 71.6% and 55.5% (log rank = 0.18). Conclusion There was no statistical significant difference in secondary patency rates between SV and PTFE in IFPB. PTFE grafts as SV grafts can be a good alternative bypass material in IFPB instead of SV grafts.
    Annals of Surgical Treatment and Research 07/2014; 87(1):35-40. DOI:10.4174/astr.2014.87.1.35
  • [Show abstract] [Hide abstract]
    ABSTRACT: The properties of Fe, Ni, and permalloy monolayer and alternating Ni-Fe/SiO<sub>2</sub> multilayer thin films prepared by high vacuum evaporation and DC sputtering have been investigated. In the case of multilayer thin films the relative permeability at high frequencies is much improved, confirming the existence of a magnetostatic coupling between the 0.2 μm thin magnetic layers. The alternating Ni-Fe/SiO <sub>2</sub> multilayer thin films are available for utilization as magnetoresistive heads and magnetoresistive sensors
    Semiconductor Conference, 1997. CAS '97 Proceedings., 1997 International; 11/1997
  • [Show abstract] [Hide abstract]
    ABSTRACT: ALDH(br) cells express high aldehyde dehydrogenase (ALDH) activity and have progenitor cell activity in several contexts. We characterized human BM ALDH(br) cells to determine whether cell sorting based on ALDH activity isolates potentially useful populations for cell therapy. We measured the expression of ALDH and cell-surface Ag by flow cytometry and compared the ability of sorted ALDH(br), and BM populations remaining after ALDH(br) cells were removed (ALDH(dim) populations), to develop into several cell lineages in culture. The ALDH(br) population comprised 1.2+/-0.8% (mean+/-SD, n=30) nucleated cells and was enriched in cells expressing CD34, CD117, CD105, CD127, CD133 and CD166, and in primitive CD34(+) CD38(-) and CD34(+) CD133(+) progenitors. Most of the CD34(+) and CD133(+) cells were ALDH(dim). ALDH(br) populations had 144-fold more hematopoietic colony-forming activity than ALDH(dim) cells and included all megakaryocyte progenitors. ALDH(br) populations readily established endothelial cell monolayers in cultures. Cells generating endothelial colonies in 7 days were 435-fold more frequent in ALDH(br) than ALDH(dim) populations. CFU-F were 9.5-fold more frequent in ALDH(br) than ALDH(dim) cells, and ALDH(br) cells gave rise to multipotential mesenchymal cell cultures that could be driven to develop into adipocytes, osteoblasts and chondrocytes. Hematopoietic, endothelial and mesenchymal progenitor cells can be isolated simultaneously from human BM by cell sorting based on ALDH activity. BM ALDH(br) populations may be useful in several cell therapy applications.
    Cytotherapy 02/2007; 9(3):259-74. DOI:10.1080/14653240701218516 · 3.29 Impact Factor
Show more


21 Reads